H.C. Wainwright raised the firm’s price target on Viridian Therapeutics (VRDN) to $34 from $27 and keeps a Buy rating on the shares. The firm expects veligrotug to meet the endpoints in chronic thyroid eye given that Tepezza demonstrated efficacy in chronic TED treatment. It thinks veligrotug will show at least comparable efficacy to Tepezza.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter